-
Mashup Score: 17Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome - 7 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM Hematology Disease Topics & Pathways: Research, Translational Research, Bioinformatics, Genomics, Computational biology, Biological Processes, Technology and Procedures, Omics technologies Jean-Baptiste Alberge, PhD 1,2,3, Ankit K. Dutta, PhD 1,2,3 *, Andrea Poletti 1,4
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Paper: Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease - 7 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Juan-Jose Garces, PhD 2 *, Tala Shekarkhand, MS 3 *, Sridevi Rajeeve, MD 1 *, Hamza Sloan Hashmi, MD 3 *, Hani Hassoun, MD 3, Malin Hultcrantz, MD 3, Neha Korde, MD 3, Carlyn
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease https://t.co/uPI3nGpgqJ - 251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease… https://t.co/MZUDB2yUS9
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W
-
-
Mashup Score: 33MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma - PubMed - 7 month(s) ago
In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment-decisions remains unclear. In a phase II trial (NCT04113018), we assessed daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction followed …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
A big shoutout to @LevineCancer #mmsm crew for bringing this study to fruition. @manisha_bhutani @PlasmaCellPete @AtrashShebli @BarryAdamP 😊🙏🏽👏🏽👏🏽👏🏽👏🏽 https://t.co/cr8r0dUDre
-
-
Mashup Score: 3Paper: Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease - 7 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Juan-Jose Garces, PhD 2 *, Tala Shekarkhand, MS 3 *, Sridevi Rajeeve, MD 1 *, Hamza Sloan Hashmi, MD 3 *, Hani Hassoun, MD 3, Malin Hultcrantz, MD 3, Neha Korde, MD 3, Carlyn
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease https://t.co/uPI3nGpgqJ - 251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease… https://t.co/MZUDB2yUS9
-
-
Mashup Score: 3Paper: Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease - 7 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Biological Processes Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA 1, Juan-Jose Garces, PhD 2 *, Tala Shekarkhand, MS 3 *, Sridevi Rajeeve, MD 1 *, Hamza Sloan Hashmi, MD 3 *, Hani Hassoun, MD 3, Malin Hultcrantz, MD 3, Neha Korde, MD 3, Carlyn
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 248 Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease https://t.co/uPI3nGpgqJ - 251 DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease… https://t.co/MZUDB2yUS9
-
-
Mashup Score: 16Paper: A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome - 8 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM Hematology Disease Topics & Pathways: Research, Translational Research, Bioinformatics, Genomics, Computational biology, Biological Processes, Technology and Procedures, Omics technologies Jean-Baptiste Alberge, PhD 1,2,3, Ankit K. Dutta, PhD 1,2,3 *, Andrea Poletti 1,4
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
**Basic/Translational Abstracts: - 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome https://t.co/oSbzH0CDX6 -358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific… https://t.co/MTRou3ET7G
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Emerging technologies, Technology and Procedures Mark R Dowling, MBBS, PhD 1,2,3, Hamish W Scott, MD 4 *, Theresa L Connor, BSc,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
**Clinical Abstracts - RRMM: 1029 CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI https://t.co/kqqZy5dNXt 1031 Phase 2… https://t.co/frEV7mvlGq
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Gordon Cook, PhD, DSc 1,2 *, Charlotte Pawlyn, PhD 3, Kara-Louise Royle 4 *, Ethan R Senior 5 *, Dax Everritt 6 *, Jenny Bird 7 *, Stella Bowcock 8 *, Bryony Dawkins, MSc 9 *, Mark Drayson 10 *, Sharon Gillson,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 673 IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial https://t.co/kKMlFqbifx - 769 Isatuximab, Lenalidomide, Bortezomib and… https://t.co/tgdSdi5UrC
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W
-
**Basic/Translational Abstracts: - 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome https://t.co/oSbzH0CDX6 -358 Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific… https://t.co/MTRou3ET7G